Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599211 | 1.00 | KDM1A (0.45) | KDM1ANPC1RXFP1KDM4EHSD17B10 | |
| SCHEMBL3599213 | 1.00 | KDM1A (0.45) | KDM1ANPC1RXFP1KDM4EHSD17B10 | |
| SCHEMBL14708134 | 0.84 | SLC9A1 (0.50) | MAPT | |
| SCHEMBL4140532 | 0.84 | SLC9A1 (0.50) | MAPT | |
| SCHEMBL19403863 | 0.84 | SLC9A1 (0.50) | MAPT | |
| SCHEMBL15805122 | 0.83 | KDM1A (0.44) | KDM1AMAOBMAPT | |
| SCHEMBL15797833 | 0.83 | KDM1A (0.44) | KDM1AMAOBMAPT | |
| SCHEMBL15797832 | 0.83 | KDM1A (0.44) | KDM1AMAOBMAPT | |
| SCHEMBL13550258 | 0.81 | KDM1A (0.43) | KDM1ANPC1RXFP1MAOB | |
| SCHEMBL13550257 | 0.81 | KDM1A (0.43) | KDM1ANPC1RXFP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| EP-2121612-B1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-10-01 | — | — | EP | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-8299102-B2 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2121612-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080511-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | WO | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| EP-1942104-A1 | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016278-A1 | HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | PTGIS, TBXAS1, EDNRA | KDM1A 1703/4885NPC1 3008/4885RXFP1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.